Skip to main navigation Skip to search Skip to main content

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

  • Siraj M Ali
  • , R Kathy Alpaugh
  • , Jamie K Buell
  • , Philip J Stephens
  • , Jian Qin Michael Yu
  • , Hong Wu
  • , Christine N Hiemstra
  • , Vincent A Miller
  • , Doron Lipson
  • , Gary A Palmer
  • , Jeffrey S Ross
  • , Massimo Cristofanilli

Research output: Contribution to journalArticlepeer-review

21 Scopus citations
Original languageEnglish
Pages (from-to)e14-e16
JournalClinical Breast Cancer
Volume14
Issue number1
DOIs
StatePublished - Feb 2014

Keywords

  • ErbB Receptors/antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Inflammatory Breast Neoplasms/drug therapy
  • Middle Aged
  • Mutation
  • Protein Kinase Inhibitors/therapeutic use
  • Quinazolines/therapeutic use

Fingerprint

Dive into the research topics of 'Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib'. Together they form a unique fingerprint.

Cite this